Thermo Fisher Scientific Opens East Coast Collaboration Center At BioLabs for Advanced Therapeutics to Help Accelerate Cell and Gene Therapy Development
Thermo Fisher Scientific Inc. announced the grand opening of its East Coast Advanced Therapies Collaboration Center (ATxCC) in Philadelphia, marking the company's second ATxCC in the United States following the opening of its Carlsbad, California, site. Together, these centers expand the company's nationwide network supporting cell and gene therapy (CGT) innovation, providing critical resources to biotech, biopharma and translational researchers developing next-generation cell-based immunotherapies. Advanced therapies represent one of the most promising frontiers in modern medicine, offering the potential to treat, and even cure, diseases once considered untreatable.
As demand for these therapies grows, so does the need for scalable, innovative solutions. The opening of Thermo Fisher's new East Coast center highlights the company's ongoing investment in enabling these breakthroughs and advancing the future of healthcare. Located within BioLabs for Advanced Therapeutics Philadelphia, a newly expanded 53,000-square-foot biotech incubator in the heart of the city, the Philadelphia ATxCC provides emerging startups and biopharma organizations with direct access to Thermo Fisher's expert scientists, advanced process development technologies and collaboration opportunities.
Thermo Fisher Scientific Inc. specializes in the design, manufacturing and marketing of laboratory and scientific equipments. Net sales (including intragroup) break down by family of products as follows:
- laboratory equipments (73.2%). Moreover, the group proposes chemical products (reagents, solvent, salts, etc.), consumable products (tubes, funnels, vials, etc.), as well as conditioning, warehousing, storage, etc.;
- scientific analysis equipments (16.7%): analyzer (of water, gas, grounds, etc.), mass spectrometers, molecular spectroscopes, microscopes, manometers, samplers, microbiology equipments, reactive agents, etc.;
- diagnostics equipment and products (10.1%).
Net sales break down by source of revenue between sales of products (58.4%) and services (41.6%).
Net sales break down geographically as follows: North America (52.5%), Europe (25.3%), Asia/Pacific (18.6%) and other (3.6%).
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Thermo Fisher Scientific Opens East Coast Collaboration Center At BioLabs for Advanced Therapeutics to Help Accelerate Cell and Gene Therapy Development
